Patients with type 2 diabetes have a three-fold increased risk of developing vascular disease with death in 75% due to a vascular complication. Large prospective studies have demonstrated the benefits of treating patients with type 2 diabetes to strict targets regarding blood pressure (BP), lipids and glucose. Using both American Diabetes Association and Joint British Societies/Guidelines we assessed the effectiveness of this `treat-to-target' policy in diabetic patients attending secondary care. Of 321 patient notes analysed 54—87% were within target for total cholesterol, 80—84% for LDL cholesterol, 77% for HDL cholesterol, 51% for triglycerides, 44—61% for systolic BP, 62% for diastolic BP and 30—44% for HbA1C. In the secondary care setting we are performing well for lipids, less well for BP and poorly for HbA1C.
Burant CF (ed.) Medical management of Type 2 Diabetes. 5th ed. Alexandria, VA, American Diabetes Association2004.
2.
American Diabetes Association.Economic costs of Diabetes in the US. In 2002. Diabetes Care2003;26:917-32.
3.
Davidson JATreatment of the patient with diabetes: importance of maintaining target HbA1C levels. Cur Med Res Opin2004;20:1919.
4.
Saydah SH, Fradkin J., Cowie CCPoor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA2004;291:335-42.
5.
UK Prospective Diabetes Study (UKPDS) Group : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet1998;352:854-65.
6.
Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with-macrovascular and microvascular complications for type 2 diabetes (UKPDS 35): prospective observational study. BMJ2000;321:405-12.
7.
Ethisham S., Barrett TG, Shaw NJType 2 diabetes in UK children an emerging problem. Diabet Med2000;17:867-71.
8.
Rosenbloom AL , Joe JR, Young RS, Winter WEEmerging epidemic of type 2 diabetes in youth . Diabetes Care1999;22:345-54.
9.
Herman WH, Teutsch SM, Geiss LSClosing the Gap: The problem of Diabetes Mellitus in the United States. Diabetes Care1985;8:391-406.
10.
Laakso M.Epidemiology of diabetic dyslipidaemia. Diabetes Review1995;340822
11.
Arauz-Pacheco C., Parrott MA, Raskin P.The treatment of hypertension in adult patients with diabetes. Diabetes Care2002;25:134-47.
12.
UK 2. UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ1998;317:703-13.
13.
Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36); prospective observational study . BMJ2000;321:412-19.
14.
Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study . Lancet2000;355:253-9.
15.
Lindholm LH , Ibsen H., Dahlof B. et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE). Lancet2002; 359:1004-10.
16.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288:2981-97.
17.
Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trial. Lancet2003; 361:2005-16.
18.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet2004;364:685-96.
19.
Standards of Medical Care.American Diabetes Association. Diabetes Care2006;29:S4-S42.
20.
Joint British Societies Guidance Version 2 on prevention of cardiovascular disease in Clinical Practice. Heart2005;91:1-52.
21.
Dauolt B., Server PS, Poultor NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perivdopril as required versus atenolol adding beudro flumethiazid as required, in the Angl-Scandivarian Cardic Outcomes Trial -bloop pressure lowering arm (ASCOT-BPLA) a multicentre randomised controlled trail. Lancet2005;366:895-906.
22.
Zauchetti A. , Julius S., Kyeldsen S. et al.Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an anlysis of findings from the VALUE trail. J Hypertens2006;24:2163-8.
23.
Skyler JS, Weinstock RS, Raskin P.Use of inhaled insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects: A 6-month randomized comparative trial. Diabetes Care2005;28:1630.
24.
Norris SL, Engelgau MM, Narayan KMEffectiveness of self-management training in type 2 diabetes; a systematic review of randomised controlled trials. Diabetes Care2001;24:561-87.
25.
Norris SL, Lau J., Smith SJ, Schmid CH, Engelgau MMSelf management education for adults with type 2 diabetes: a meta analysis of the effect on glycaemic control. Diabetes Care2002;25:1159-71.
26.
6. Gary TL, Genkinger JM, Guallar E., Peyrot M., Brancati FLMeta-analysis of randomized educational and behavioural interventions in type 2 diabetes. Diabetes Educ2003;29:488-501.
27.
Skinner TC, Davies MJ, Heller S., Khunti K.The effects of a structured education programme on illness beliefs, quality of life and physical activity in individuals newly diagnosed with type 2 diabetes.Results from the DESMOND pilot group. Diabetic Medicine2005.
28.
Davies MJ, Heller S., Khunti K., Skinner TCThe DESMOND programme: from pilot phase to randomised control trial in a study of structured group education for people newly diagnosed with type 2 diabetes mellitus. Diabetic Medicine2005;64:369-77.
